Affordable Access

Publisher Website

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics

Authors
Journal
Frontiers in Pharmacology
1663-9812
Publisher
Frontiers Media SA
Publication Date
Volume
3
Identifiers
DOI: 10.3389/fphar.2012.00152
Keywords
  • Pharmacology
  • Perspective Article
Disciplines
  • Biology
  • Medicine
  • Pharmacology
  • Philosophy

Abstract

Direct-to-consumer (DTC) DNA testing has grown from contentious beginnings into a global industry, by providing a wide range of personal genomic information directly to its clients. These companies, typified by the well-established 23andMe, generally carry out a gene-chip analysis of single-nucleotide polymorphisms (SNPs) using DNA extracted from a saliva sample. These genetic data are then assimilated and provided direct to the client, with varying degrees of interpretation. Although much debate has focused on the limitations and ethical aspects of providing genotypes for disease risk alleles, the provision of pharmacogenetic results by DTC companies is less studied. We set out to evaluate current DTC pharmacogenetics offerings, and then to consider how these services might best evolve and adapt in order to play a potentially useful future role in delivery of personalized medicine.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

[Microbubbles: current state and future prospects]...

on Giornale italiano di nefrologi... 2012

[Current states and future prospects of kidney fai...

on Nihon Naika Gakkai zasshi. The... Jul 10, 1998

Pharmacogenetics in solid organ transplantation: c...

on Transplantation Reviews Jan 01, 2008

Direct thrombin inhibitors: current status and fut...

on Expert opinion on investigatio... September 1999
More articles like this..